Physician profile
Dina Rivera
NPI 1932384807
$14,340.97
in general payments reported to CMS, 2019-2025
54 companies · $2,427 in 2025
The $2,427 reported for 2025 was more than what 80% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $990 · 2020: $16.76 · 2021: $1,485 · 2022: $3,264 · 2023: $3,234 · 2024: $2,924 · 2025: $2,427.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,585.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,584.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,868.39 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Novo Nordisk INC | $1,829.57 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $977.13 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Amgen INC. | $952.82 | 2019-2025 | Repatha, Evenity, Tepezza |
| Astrazeneca Pharmaceuticals Lp | $767.06 | 2019-2023 | Farxiga |
| Dexcom, INC. | $764.17 | 2019-2025 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $629.63 | 2019-2025 | Korlym |
| Cequr Corporation | $566.73 | 2022-2025 | Cequr Simplicity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $557.04 | 2019-2025 | Jardiance, Synjardy |
| Mannkind Corporation | $449.29 | 2019-2025 | Afrezza |
| Novartis Pharmaceuticals Corporation | $437.75 | 2022-2025 | |
| Intuity Medical INC | $436.07 | 2022-2023 | Pogo Automatic Blood Glucose Monitoring System |
| Xeris Pharmaceuticals, INC. | $384.88 | 2021-2025 | Recorlev, Gvoke Hypopen |
| Insulet Corporation | $362.87 | 2019-2025 | Omnipod |
| Abbvie INC. | $315.44 | 2019-2025 | Ubrelvy, Synthroid |
Show all 54 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascensia Diabetes Care US INC. | $294.88 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $239.10 | 2019-2025 | |
| Zealand Pharma US, INC. | $220.02 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $161.11 | 2022-2023 | Cycloset |
| Sequel Med Tech, LLC | $146.51 | 2025 | Twiist |
| Amarin Pharma, INC. | $133.39 | 2019-2023 | |
| Antares Pharma, INC. | $128.67 | 2021-2025 | Xyosted, Tlando, Nocdurna |
| Horizon Therapeutics Plc | $112.66 | 2021-2023 | Tepezza |
| Ipsen Biopharmaceuticals, INC | $107.30 | 2021-2023 | Somatuline Depot |
| Neurocrine Biosciences, INC. | $104.51 | 2025 | |
| Tolmar, INC. | $97.11 | 2024-2025 | Jatenzo |
| Esperion Therapeutics, INC. | $92.62 | 2021-2022 | |
| Beta Bionics, INC. | $91.25 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Alexion Pharmaceuticals, INC. | $80.28 | 2022-2025 | Strensiq |
| Medtronic, INC. | $75.91 | 2021-2025 | Minimed 780g, Inceptiv, Vanta Adaptivestim |
| Radius Health, INC. | $74.14 | 2019-2025 | Tymlos |
| Recordati_rare_diseases_inc. | $74.03 | 2022-2025 | Signifor Lar |
| Halozyme INC | $64.62 | 2023 | |
| Kyowa Kirin, INC. | $63.21 | 2024-2025 | Crysvita |
| Averitas Pharma INC. | $59.91 | 2023-2024 | Qutenza |
| Eusa Pharma (US) LLC | $53.63 | 2022 | |
| Shire North American Group INC | $51.74 | 2019 | |
| Amneal Pharmaceuticals LLC | $46.24 | 2025 | Unithroid |
| Merck Sharp & Dohme LLC | $45.01 | 2019-2022 | |
| Nevro Corp. | $43.06 | 2023 | Senza |
| Ibsa Pharma INC. | $42.70 | 2021-2022 | |
| Eisai INC. | $38.13 | 2019 | |
| Valeritas, INC. | $36.84 | 2019 | |
| Medtronic Minimed, INC. | $33.86 | 2019 | |
| Boston Scientific Corporation | $32.72 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $31.13 | 2021-2022 | |
| Bigfoot Biomedical INC | $27.96 | 2022 | |
| Amryt Pharma Holdings Ltd | $25.15 | 2023 | Mycapssa |
| Becton, Dickinson and Company | $25.08 | 2022 | |
| Ascendis Pharma Endocrinology INC | $24.18 | 2025 | Yorvipath |
| Tandem Diabetes Care, INC. | $21.20 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Grt US Holding, INC. | $21.12 | 2022 | |
| Pfizer INC. | $14.80 | 2022 | |
| Kvk-Tech, INC. | $6.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dina Rivera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.